Enzymatica AB

The Board of Directors of Enzymatica AB decides on rights issue of SEK 98.7 million - Seite 3

The Board of Directors' decision on the rights issue is subject to approval by an Extraordinary General Meeting to be held on November 5, 2018. Notice of the Extraordinary General Meeting will be announced in a separate press release and will be published shortly in Post- och Inrikes Tidningar. The notice will also be advertised in Dagens Industri.

Preliminary timetable for rights issue

November 5, 2018             Extraordinary General Meeting

November 8, 2018             Last day of trading in the share including subscription rights

November 9, 2018             First day of trading in the share excluding subscription rights

November 12, 2018           Record date for participation in the rights issue

November 14-28, 2018     Subscription period

November 14-26, 2018     Trading in subscription rights

December 3, 2018             Estimated date of announcement of the outcome of the rights issue

The company will prepare a prospectus for the rights issue which will be published before the subscription period begins.

Adviser

Erik Penser Bank AB is Enzymatica's financial adviser in connection with the rights issue. Mannheimer Swartling is the Company's legal adviser.

The information in this press release is information that Enzymatica is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 8:00 CET on 18 October, 2018.

For more information, please contact:

Fredrik Lindberg, CEO, Enzymatica AB
Tel: [phone] | Email: [e-mail]
Carl-Johan Wachtmeister, Head of Corporate Communications, Enzymatica AB
Tel.: [phone] | Email: [e-mail]

About Enzymatica AB
Enzymatica AB is a Swedish life science company that develops and sells medical devices for infection-related diseases. The products are based on a barrier technology that includes marine enzymes. The company's first product is ColdZyme Mouth Spray, which can prevent colds and reduce the duration of disease. The product has been launched in about ten markets. The strategy is to continue to grow by strengthening the Company's position in existing markets and expanding into new geographic markets through established partners. The company has its headquarters in Lund and is listed on Nasdaq First North. For more information, visit: www.enzymatica.com.

Enzymatica's certified adviser is Erik Penser Bank.

Enzymaticas Certified Adviser är Erik Penser Bank.

För mer information, kontakta:

---

This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Enzymatica AB via Globenewswire